$MCRB

Seres Therapeutics, having sold VOWST to Nestlé and reduced its workforce, has extended its financial runway until Q2 2026. The company's next significant value driver is its SER-155 program, which demonstrated strong Phase 1b data with a 77% reduction in BSI risk and received FDA Breakthrough designation for gut-driven bloodstream infections in allo-HSCT patients. Despite a relatively reasonable valuation, the risk of dilution for this thinly traded microcap warrants a "Hold" rating.